Increasing Prevalence of Cancer Fuel to the Asia Pacific Endoscopy Procedures Market
Cancer is a major public health problem and leading cause of death across the world. Increasing gastrointestinal disorders and cancer cases also accelerate the endoscope adoption and market growth. Colorectal cancer is increasingly affecting populations in Asian countries. According to the International Agency for Research on Cancer & GLOBOCON, ~1 million new colorectal cancer cases were reported in Asia in 2020. Japan, China, Malaysia, Singapore, and South Korea witnessed high prevalence rates compared to other countries in the region. Additionally, Asia had the highest global percentages of incident (51.8%) and death (52.4%) colorectal cancer cases (all age groups and genders) per 100,000 people in 2018. Furthermore, this disease has been increasingly prevalent throughout Asia, with certain regional and geographic variations. Westernized food, an aging population, smoking, physical inactivity, and other risk factors are the major causes of this increase in CRC. Furthermore, the most recent estimates from GLOBOCAN for 2020 show that only 60% (1,315,136) of newly diagnosed cases of lung cancer and 62% (1,112,517) of all lung cancer-related fatalities occurred in Asia. Also, gastric cancer (GC) is considered one of the most dangerous cancers in the world; in 2020, there were over one billion new cases and 783,000 deaths from GC. Asian nations have a notably high incidence of GC, and Eastern Asia has recently recorded more than 60% of GC cases. Compared to populations in Western nations, stomach cancer has historically impacted East Asian populations disproportionately. In Japan, stomach cancer is the most frequent cancer among men, and half of all occurrences of the disease occur in China. Inflammatory bowel disease (IBD) is a term for two conditions - ulcerative colitis (UC) and Crohn’s disease (CD). Moreover, in the last few years, cases of IBD have increased worldwide due to a sedentary lifestyle, changing dietary habits, stress, and poor nutritional choices. The intake of processed foods and trans-fats has drastically increased globally. Also, Asia saw a rise in IBD cases from 763,544 in 1990 to 1,992,221.5 in 2019. Asia had the highest overall incidence and prevalence of IBD among the four continents in 2019. Also, according to the IBS Global Impact Report, in 2016, the estimated prevalence of irritable bowel syndrome in Asia was 9.6%. Further, chronic inflammation and reduced immunosurveillance caused by IBD may contribute to the development of gastric cancer. Thus, the rising burden of cancer in the region indicates the high requirement for endoscopic devices, thus driving the market growth.Asia Pacific Endoscopy Procedures Market Overview
The endoscopic procedures market in Asia Pacific is segmented into India, China, Japan, Australia, South Korea, and the Rest of Asia Pacific. This region accounted for over 26.05% of the global endoscopy procedure market owing to a large population base in countries such as China and India. The increasing focus of market players on introducing new products or therapies is the major factor promoting the market growth.Asia Pacific Endoscopy Procedures Market Revenue and Forecast to 2030 (US$ Million)
Asia Pacific Endoscopy Procedures Market Segmentation
The Asia Pacific endoscopy procedures market is segmented into procedure, offering, product type, and end user.Based on procedure, the Asia Pacific endoscopy procedures market is segmented into endoscopic retrograde cholangiopancreatography (ERCP), endoscopic submucosal dissection (ESD), peroral endoscopic myotomy (POEM), endoscopic ultrasound (EUS), interventional pulmonology and laparoscopy, arthroscopy and bronchoscopy, colonoscopy and colposcopy, proctoscopy and thoracoscopy, and others. The arthroscopy and bronchoscopy segment held the largest share of the Asia Pacific endoscopy procedures market in 2022.
Based on offering, the Asia Pacific endoscopy procedures market is segmented endoscopes, ERCP accessories, visualization system, head positioner and endotherapy injection needles, sampling device and device clip and electrosurgical knife, endoscopic ultrasound guided devices, guidewire, forceps, snare, irrigation/insufflation tubing systems, probes, hemostats clip, polyps’ traps, single-use valves, trocar sleeves and tissue scissors and cutters, retrieval devices, and Others (Kits/Stents/Energy Devices/ Transport pad/Cleaning Brush/OT Lights etc.). The endoscopes segment held the largest share of the Asia Pacific endoscopy procedures market in 2022.
Based on product type, the Asia Pacific endoscopy procedures market is bifurcated into disposable and reusable. The reusable segment held a larger share of the Asia Pacific endoscopy procedures market in 2022.
Based on end user, the Asia Pacific endoscopy procedures market is segmented into hospitals and clinics, ambulatory surgical centres, diagnostic laboratories, and others. The hospitals and clinics segment held the largest share of the Asia Pacific endoscopy procedures market in 2022.
Based on country, the Asia Pacific endoscopy procedures market is segmented int o the India, China, Japan, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific endoscopy procedures market in 2022.
Stryker Corp, FUJIFILM Holdings Corp, Merit Medical Systems Inc, Smith & Nephew Plc, Arthrex Inc, Steris Plc, Conmed Corp, Olympus Corp, Boston Scientific Corp, and Cook Medical LLC, are some of the leading companies operating in the Asia Pacific endoscopy procedures market.
Table of Contents
Executive Summary
At 7.3% CAGR, the Asia Pacific Endoscopy Procedures Market is Speculated to be Worth US$ 14,103.00 million by 2030.According to this research, the Asia Pacific endoscopy procedures market was valued at US$ 8,044.94 million in 2022 and is expected to reach US$ 14,103.00 million by 2030, registering a CAGR of 7.3% from 2022 to 2030. Technological advancements leading to enhanced applications and increasing prevalence of cancer attributed to the Asia Pacific endoscopy procedures market expansion.
On April 12, 2021, Cosmo Pharmaceuticals NV announced the FDA approval of the GI Genius intelligent endoscopy system, its revolutionary device for lesion detection during colonoscopy. The device is the first of its kind to obtain the FDA approval through the De Novo application. The device operates in real time to assist the endoscopist in the detection of lesions, is very simple to use and is compatible with all endoscopes. Cosmo is the sole manufacturer. On December 2019, Boston Scientific Corporation launched “EXALT Model D” a Single-Use Duodenoscope for endoscopic retrograde cholangiopancreatography procedures. This is the world’s first single use duodenoscope. The third generation EXALT Model D Single-Use Duodenoscope has incorporated several design updates based on physician feedback that are intended to improve the overall user experience. Thus, all these recent developments are expected to provide growth opportunities for the market over the forecast period.
On the contrary, risks of infections associated with endoscopic procedures hampers the Asia Pacific endoscopy procedures market.
Based on procedure, the Asia Pacific endoscopy procedures market is segmented into endoscopic retrograde cholangiopancreatography (ERCP), endoscopic submucosal dissection (ESD), peroral endoscopic myotomy (POEM), endoscopic ultrasound (EUS), interventional pulmonology and laparoscopy, arthroscopy and bronchoscopy, colonoscopy and colposcopy, proctoscopy and thoracoscopy, and others. The arthroscopy and bronchoscopy segment held 24.2% share of Asia Pacific endoscopy procedures market in 2022, amassing US$ 1,943.51 million. It is projected to garner US$ 3,633.72 million by 2030 to expand at 8.1% CAGR during 2022-2030.
Based on offering, the Asia Pacific endoscopy procedures market is segmented into endoscopes, ERCP accessories, visualization system, head positioner and endotherapy injection needles, sampling device and device clip and electrosurgical knife, endoscopic ultrasound guided devices, guidewire, forceps, snare, irrigation/insufflation tubing systems, probes, hemostats clip, polyps’ traps, single-use valves, trocar sleeves and tissue scissors and cutters, retrieval devices, and Others (Kits/Stents/Energy Devices/ Transport pad/Cleaning Brush/OT Lights etc.). The endoscopes segment held 32.8% share of Asia Pacific endoscopy procedures market in 2022, amassing US$ 2,641.70 million. It is projected to garner US$ 4,696.36 million by 2030 to expand at 7.5% CAGR during 2022-2030.
Based on product type, the Asia Pacific endoscopy procedures market is bifurcated into disposable and reusable. The reusable segment held 78.1% share of Asia Pacific endoscopy procedures market in 2022, amassing US$ 6,284.99 million. It is projected to garner US$ 10,337.73 million by 2030 to expand at 6.4% CAGR during 2022-2030.
Based on end user, the Asia Pacific endoscopy procedures market is segmented into hospitals and clinics, ambulatory surgical centers, diagnostic laboratories, and others. The hospitals and clinics segment held 58.5% share of Asia Pacific endoscopy procedures market in 2022, amassing US$ 4,705.79 million. It is projected to garner US$ 8,146.63 million by 2030 to expand at 7.1% CAGR during 2022-2030.
Based on country, the Asia Pacific endoscopy procedures market has been categorized into the India, China, Japan, Australia, South Korea, and the Rest of Asia Pacific. Our regional analysis states that China captured 37.1% share of Asia Pacific endoscopy procedures market in 2022. It was assessed at US$ 2,988.57 million in 2022 and is likely to hit US$ 5,272.85 million by 2030, exhibiting a CAGR of 7.4% during 2022-2030.
Key players operating in the Asia Pacific endoscopy procedures market are Stryker Corp, FUJIFILM Holdings Corp, Merit Medical Systems Inc, Smith & Nephew Plc, Arthrex Inc, Steris Plc, Conmed Corp, Olympus Corp, Boston Scientific Corp, and Cook Medical LLC, among others.
In May-2023, Stryker had completed the acquisition of Cerus Endovascular Ltd. The acquisition of Cerus Endovascular is highly complementary to Stryker’s Neurovascular business and strengthens the hemorrhagic portfolio globally. In Jun-2022, Stryker had opened its new research and development facility, Stryker’s Global Technology Centre, at the International Tech Park, Gurgaon. The 150,000-square-foot facility further supported the company’s mission to make healthcare better.
Companies Mentioned
- Stryker Corp
- FUJIFILM Holdings Corp
- Merit Medical Systems Inc
- Smith & Nephew Plc
- Arthrex Inc
- Steris Plc
- Conmed Corp
- Olympus Corp
- Boston Scientific Corp
- Cook Medical LLC
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 165 |
Published | December 2023 |
Forecast Period | 2022 - 2030 |
Estimated Market Value in 2022 | 8.04 Billion |
Forecasted Market Value by 2030 | 14.1 Billion |
Compound Annual Growth Rate | 7.3% |
Regions Covered | Asia Pacific |
No. of Companies Mentioned | 10 |